Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which engages in the proprietary research and development of innovative medicine products for cancers and other Androgen receptor-related diseases. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-05-22. The firm's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers dermatology (such as hair loss, acne) and tumor indications. The firm has two core drugs in the dermatology field, KX-826 and GT20029. The firm's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.
Follow-Up Questions
Kintor Pharmaceutical Ltd 的 CEO 是谁？
Dr. Tong Youzhi 是 Kintor Pharmaceutical Ltd 的 Executive Chairman of the Board，自 2018 加入公司。
KNTPF 股票的价格表现如何？
KNTPF 的当前价格为 $0.2688，在上个交易日 decreased 了 0%。
Kintor Pharmaceutical Ltd 的主要业务主题或行业是什么？
Kintor Pharmaceutical Ltd 属于 Biotechnology 行业，该板块是 Health Care
